The PE Ratio as of November 2024 (TTM) for Pliant Therapeutics, Inc. (PLRX) is -3.87

According to Pliant Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.87. This represents a change of -10.13% compared to the average of -4.31 of the last 4 quarters.

Pliant Therapeutics, Inc. (PLRX) Historical PE Ratio (quarterly & annually)

How has PLRX PE Ratio performed in the past?

The mean historical PE Ratio of Pliant Therapeutics, Inc. over the last ten years is 574.31. The current -3.87 PE Ratio has changed -167.39% with respect to the historical average. Over the past ten years (40 quarters), PLRX's PE Ratio was at its highest in in the March 2020 quarter at 15.08. The PE Ratio was at its lowest in in the March 2021 quarter at -15.33.

Pliant Therapeutics, Inc. (PLRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Pliant Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pliant Therapeutics, Inc. (PLRX) Average PE Ratio

How has PLRX PE Ratio performed in the past?

The current PE Ratio of Pliant Therapeutics, Inc. (PLRX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Pliant Therapeutics, Inc. (PLRX) PE Ratio vs. Peers

How is PLRX’s PE Ratio compared to its peers?

Pliant Therapeutics, Inc.’s PE Ratio is less than Relay Therapeutics, Inc. (-1.93), greater than Stoke Therapeutics, Inc. (-6.11), less than Black Diamond Therapeutics, Inc. (-1.96), greater than Arvinas, Inc. (-6.04), less than 89bio, Inc. (-3.25), greater than Madrigal Pharmaceuticals, Inc. (-14.57), greater than Arcellx, Inc. (-120.42), greater than Dyne Therapeutics, Inc. (-10.17), greater than Cytokinetics, Incorporated (-10.02), greater than Revolution Medicines, Inc. (-16.70), greater than Syndax Pharmaceuticals, Inc. (-4.63), greater than Viridian Therapeutics, Inc. (-5.22), less than Inozyme Pharma, Inc. (-1.84), less than TCR2 Therapeutics Inc. (-0.38), less than Atreca, Inc. (-0.06), less than Passage Bio, Inc. (-0.45),

Build a custom stock screener for Pliant Therapeutics, Inc. (PLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pliant Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pliant Therapeutics, Inc. (PLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pliant Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.